Article

Close follow-up vital to patients with acute attack ofprimary-angle closure

Patients with acute attack of primary-angle closure (APAC) needmuch closer follow-up, since it may result in severe vision loss inthe affected eye in a substantial number of patients, said DavidFriedman, MD, MPH, associate professor at the Wilmer Eye Institute,Baltimore. He added, though, that the risk of vision problems islow in the contralateral eyes.

Patients with acute attack of primary-angle closure (APAC) need much closer follow-up, since it may result in severe vision loss in the affected eye in a substantial number of patients, said David Friedman, MD, MPH, associate professor at the Wilmer Eye Institute, Baltimore. He added, though, that the risk of vision problems is low in the contralateral eyes.

Dr. Friedman and colleagues studied the natural history of APAC in Singapore, re-examining charts from an island-wide registry and also looking at patients diagnosed with APAC at a hospital. They ultimately located and examined 90 patients. Their mean age at the time of the attack was 62; 68% were female; and 87% of the study population was Chinese.

"Acute attack can result in severe vision loss in a substantial proportion of individuals," Dr. Friedman said. "About 10% of these eyes are blind with glaucoma and many more with low vision and blindness from cataract. Contralateral eyes in comparison do quite well. Some had glaucoma at presentation, but fewer than 10% had or required trabeculectomy to control eye pressure."

The main cause of decreased vision in the contralateral eyes was unoperated cataract; one patient had corneal decompensation.

An estimated 100,000 cases per year occur in China, but this could triple by 2050 as a large cohort of the population ages, Dr. Friedman said. The condition is rare in individuals under the age of 40.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.